Skip to main content
SpringerLink
Log in

Inhibition of Atherosclerosis by Angiotensin II Type 1 Receptor Antagonists

  • Current Opinion
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–8.

    Article  PubMed  CAS  Google Scholar 

  2. Seeger H, Mueck AO, Lippert TH. Effects of valsartan and 17-beta-estradiol on the oxidation of low-density lipoprotein in vitro. Coron Artery Dis. 2000;11:347–9.

    Article  PubMed  CAS  Google Scholar 

  3. Raiden S, Giordano M, Andonegui G, et al. Losartan, s selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formyl-methionyl-leucyl-phenylalanine to neutrophil receptors. J Pharmacol Exp Ther. 1997;281:624–8.

    PubMed  CAS  Google Scholar 

  4. Hornig B, Köhler C, Schlink D, et al. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B1-dependent mechanism. Hypertension. 2003;41:1092–6.

    Article  PubMed  CAS  Google Scholar 

  5. Volpe M, Paolis P. Angiotensin II AT” subtype receptors: an emerging target for cardiovascular therapy. Ital Heart J. 2000;1:96–103.

    PubMed  CAS  Google Scholar 

  6. Ono H, Ishimitsu T. Effects of angiotensin II type 1 and 2 receptor on apoptosis. Nippon Rinsho. 2002;60:1887–92.

    PubMed  Google Scholar 

  7. Yau L, Wilson DP, Werner JP, et al. Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty. Am J Physiol Heart Circ Physiol. 2001;261:1648–56.

    Google Scholar 

  8. Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55:976–82.

    Article  PubMed  CAS  Google Scholar 

  9. Hirohata A, Yamamoto K, Miyoshi T, et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis. 2012;220:134–8.

    Article  PubMed  CAS  Google Scholar 

  10. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5:301–14.

    Article  PubMed  CAS  Google Scholar 

  11. Iwai M, Nakaoka H, Senba I, et al. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodelling. Hypertension. 2012;60:137–44.

    Article  PubMed  CAS  Google Scholar 

  12. Guerin P, Sauzeau V, Rolli-Derkinderen M, et al. Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res. 2005;42:21–8.

    Article  PubMed  CAS  Google Scholar 

  13. Cohn JN, Anand IS, Latini R, Valsartan Heart Failure Trial Investigators, et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108:1306–9.

    Article  PubMed  CAS  Google Scholar 

  14. Amano T, Matsubara T, Izana H, et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol. 2006;97:785–8.

    Article  PubMed  CAS  Google Scholar 

  15. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. Circulation. 1999;100:1056–64.

    Article  PubMed  CAS  Google Scholar 

  16. Okada T, Yamamoto H, Okimoto T, et al. Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents. Circ J. 2011;75:1641–8.

    Article  PubMed  CAS  Google Scholar 

  17. Okumura M, Iwai M, Ide A, et al. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension. 2005;46:577–83.

    Article  PubMed  CAS  Google Scholar 

  18. Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med. 2006;45:581–7.

    Article  PubMed  Google Scholar 

  19. Bahlmann FH, de Groot K, Mueller O, et al. Stimulation of endothelial progenitor cells. A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45:526–9.

    Article  PubMed  CAS  Google Scholar 

  20. Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197–201.

    Article  PubMed  CAS  Google Scholar 

  21. Anand IS, Latini R, Florea VG, for the Val-HeFT Investigators, et al. C-reactive protein in heart failure, prognostic value and the effect of valsartan. Circulation. 2005;112:1428–34.

    Article  PubMed  CAS  Google Scholar 

  22. Ridker PM, Danielson E, Rifai N, Val-MARC Investigators, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:73–9.

    Article  PubMed  CAS  Google Scholar 

  23. Krämer J, Ruf RG, Schmidt S, et al. The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial – a multicenter study of AT1-receptor blocker therapy in coronary stenting. J Invasive Cardiol. 2008;20:205–10.

    PubMed  Google Scholar 

  24. Yokoyama J, Higuma T, Tomita H, et al. Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. Int J Cardiol. 2009;132:114–20.

    Article  PubMed  Google Scholar 

  25. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.

    Article  PubMed  CAS  Google Scholar 

  26. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.

    Article  PubMed  CAS  Google Scholar 

  27. Yusuf S, Teo KK, Pogue J, for the ONTARGET Investigators, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

    Article  PubMed  CAS  Google Scholar 

  28. Kun X, Yong L, Bo J, et al. Neointimal hyperplasia inhibition effect of angiotensin II type 1 receptor blockers in patients after coronary stent implantation: a meta-analysis. Am J Cardiovasc Drugs. 2011;11:209–13.

    Article  PubMed  Google Scholar 

  29. Peters S, Koehler B, Steffen H, et al. Late lumen loss and follow-up diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions. Int J Cardiol. 2010;142:29–32.

    Article  PubMed  Google Scholar 

  30. Peters S. Comparison of efficacy of low- (80 mg/d) and high- (160–320 mg/d) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs. 2008;8:83–7.

    Article  PubMed  Google Scholar 

  31. Peters S, Trümmel M, Meyners W, et al. Valsartan versus ACE inhibition after bare metal stent implantation – results of the VALVACE trial. Int J Cardiol. 2005;98:331–5.

    Article  PubMed  Google Scholar 

  32. Peters S, Götting B, Trümmel M, et al. Valsartan for the prevention of restenosis after stenting of type B2/C lesions: the Val-PREST trial. J Invasive Cardiol. 2001;13:93–7.

    PubMed  CAS  Google Scholar 

  33. Wakeyama T, Ogawa H, Iida H, et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J. 2003;67:519–22.

    Article  PubMed  CAS  Google Scholar 

  34. Yoshida O, Hirayama H, Nanasato M, et al. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J. 2005;149:e2.

    Article  PubMed  Google Scholar 

  35. Iwata A, Miura S, Imazumi S, et al. Valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J. 2007;71:31–8.

    Article  Google Scholar 

Download references

Acknowledgments

Dr. Stefan Peters has no conflicts of interest that might be relevant to the contents of this review.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Klinikum Salzgitter GmbH, Kattowitzer Str. 191, 38226, Salzgitter, Germany

    Stefan Peters

Authors
  1. Stefan Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Peters.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peters, S. Inhibition of Atherosclerosis by Angiotensin II Type 1 Receptor Antagonists. Am J Cardiovasc Drugs 13, 221–224 (2013). https://doi.org/10.1007/s40256-013-0017-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-013-0017-4

Keywords

Search

Navigation